TABLE 1.
Summary of Features in Selected Clinical Trials on OMPC
| Trial | Imaging modality | Oligometastatic definition | Oligometastatic therapy | Outcome measure | Reference |
|---|---|---|---|---|---|
| ORIOLE | CT, BS | ≤3 bone or LN | SABR vs. observation | Progression at 6 m | 54 |
| POPSTAR | 18F-NaF PET/CT | ≤3 bone | SABR | Radiographic PFS | 55 |
| RAVENS | CT, BS | ≤3 bone or ST (at least 1 bone) | SABR + 223RaCl2 | PFS | 56 |
| STOMP | Choline PET/CT | ≤3 bone or LN | Surveillance vs. SABR | ADT-free survival | 61 |
| LOCATE | 18F-fluciclovine PET/CT | ≤5 extraprostatic (≤3 in any single organ) | NA | Change in management | 64 |
| TROD 09-004 | PSMA PET/CT | ≤5 bone | SABR | 2-y PFS | 73 |
| OLI-P | PSMA PET/CT | ≤5 bone or LN | SABR | Time to ADT initiation; time to PSA progression | 75 |
| BULLSEYE | PSMA PET/CT | ≤5 bone or LN | 177Lu-PSMA-617 vs. SOC (deferred ADT) | Progression at 24 wk | 78 |
BS = bone scan; LN = lymph node; NA = not applicable; SOC = standard of care; ST = soft tissue.